Trending...
- DanReDev, Kaufman Development & Oldivai Announce Major 2026 Projects Nationwide - 112
- "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide - 112
- Consortium Media Appoints Jennifer Curtis-Neves as President of Consortium Media - 110
HAYWARD, Calif., Feb. 3, 2023 /PRNewswire/ -- Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present the Avirmax BioPharma Inc (ABI)'s progress in the innovation and development of genetic medicines for glaucoma treatment at Glaucoma 360 New Horizons Forum at The Westin St. Francis in San Francisco, Feb 03, 2023. Since its founding, Avirmax Biopharma Inc (ABI) has been focusing on developing an effective gene therapy product, ABI-902 for glaucoma treatment. Intravitreal administration of ABI-902 has demonstrated retinal ganglion cell (RGC) protection against N-methyl-D-Asparate (NMDA) excitotoxicity in mice and rats of partial optic nerve transection (pONT) measured by Detection of Apoptosing Retinal Cell (DARC) imaging technology. ABI-902 is manufactured by Avirmax CMC Inc.
Now in its 12th year, the Glaucoma 360 New Horizons Forum unites key clinical, industrial, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.
More on The Californer
Glaucoma is the second largest eye disease that leads to blindness in advanced stages. About 3 million individuals in USA and 80 million individuals worldwide are affected and the number expected to rise to 111 million globally by 2040. The main mechanism for glaucoma-induced blindness is the irreversible death of RGCs. Human eye has ~1.2 to 1.5 million RGCs which will never regenerate after glaucoma-related cell death. Drugs available in market target the IOP reduction and slow down the RGC death. Hopes for better treatment of glaucoma patients reside in protecting RGCs and lowering IOP simultaneously.
Avirmax Biopharma Inc. (ABI) is a subsidiary of Avirmax Inc., a San Francisco Bay Area based company working on genetic medicine. Avirmax Inc. specializes in developing rAAV mediated therapeutics for ocular diseases using its proprietary protein and rAAV engineering technologies. Visit us at avirmaxBP.com for more information.
Contact
Please contact
June Song, Associate Director for Operations
Email : [email protected]
Tel: +1-510-641-0201
Address
25503 Whitesell Street
Hayward 94545 CA
USA
SOURCE Avirmax
Now in its 12th year, the Glaucoma 360 New Horizons Forum unites key clinical, industrial, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.
More on The Californer
- Clean Comedy Kings Debuts At Black Oak Casino Saturday January 3rd
- Golden Paper Identifies Global Growth in Packaging Papers and Upgrades Its High-End Production Capacity
- Car Wash in Northridge CA Stays Open Late Until 10 PM
- Live Performance at the Bal Theater by Angel Sessions
- FASTMAX Launches Modern, AI-Enabled Tax Preparation for Everyday Americans
Glaucoma is the second largest eye disease that leads to blindness in advanced stages. About 3 million individuals in USA and 80 million individuals worldwide are affected and the number expected to rise to 111 million globally by 2040. The main mechanism for glaucoma-induced blindness is the irreversible death of RGCs. Human eye has ~1.2 to 1.5 million RGCs which will never regenerate after glaucoma-related cell death. Drugs available in market target the IOP reduction and slow down the RGC death. Hopes for better treatment of glaucoma patients reside in protecting RGCs and lowering IOP simultaneously.
Avirmax Biopharma Inc. (ABI) is a subsidiary of Avirmax Inc., a San Francisco Bay Area based company working on genetic medicine. Avirmax Inc. specializes in developing rAAV mediated therapeutics for ocular diseases using its proprietary protein and rAAV engineering technologies. Visit us at avirmaxBP.com for more information.
Contact
Please contact
June Song, Associate Director for Operations
Email : [email protected]
Tel: +1-510-641-0201
Address
25503 Whitesell Street
Hayward 94545 CA
USA
SOURCE Avirmax
Filed Under: Business
0 Comments
Latest on The Californer
- NAFMNP Awarded USDA Cooperative Agreement to Continue MarketLink Program Under FFAB
- Shore Scripts Announces Fall 2025 Short Film Fund Grant Recipients Al Benoit and Ericka Lavin
- California: Governor Newsom launches new initiatives to partner with tech policy experts and accelerate responsible AI in state government
- Costa Oil - 10 Minute Oil Change Surpasses 70 Locations with Construction of San Antonio, TX Stores — Eyes Growth Via Acquisition or Being Acquired
- LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
- Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- Children Rising Appoints Marshelle A. Wilburn as New Executive Director
- Fairmint CEO Joris Delanoue Elected General Director of the Canton Foundation
- Sleep Basil Mattress Co.'s Debuts New Home Page Showcasing Performance Sleep Solutions for Active Denver Lifestyles
- Bent Danholm Joins The American Dream TV as Central Florida Host
- Ship Overseas Inc Expands Heavy Equipment Shipping Operations into Africa
- The Nature of Miracles Celebrates 20th Anniversary Third Edition Published by DreamMakers Enterprises LLC
- Inboox.ai Launches Searchable Library of Real Marketing Emails Powered by AI Analysis
- Artificial Intelligence Leader Releases Children's Book on Veterans Day
- California continues to lead the nation in fusion energy, investing in technology of the future
- Felicia Allen Hits #1 Posthumously with "Christmas Means Worship"
- CCHR Documentary Probes Growing Evidence Linking Psychiatric Drugs to Violence
- IEI Introduces HTB-300-MTL-H: Ultra-Compact Medical AI Embedded System
- Mesa West Capital Funds $30 MM Loan for Acquisition of Industrial Asset in San Francisco Bay Area